New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
05:51 EDTPFE, VRX, MYL, ACTPfizer's generics unit attracts several suitors, Reuters reports
Valeant Pharmaceuticals (VRX), Actavis (ACT) and Mylan (MYL) are each interested in buying Pfizer's (PFE) branded generics business, sources say, even though there are no ongoing discussions at this point, reports Reuters.Reference Link
News For VRX;ACT;MYL;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 27, 2015
17:04 EDTACTShire granted petitiion by U.S. Supreme Court
Subscribe for More Information
07:16 EDTPFEPfizer drops 2.7% after FY15 outlook miss expectations
Subscribe for More Information
07:07 EDTPFEPfizer sees FY15 adjusted EPS $2.00-$2.10, consensus $2.18
Subscribe for More Information
07:01 EDTPFEPfizer reports Q4 adjusted EPS 54c, consensus 53c
Reports Q4 revenue $13.1B, consensus $12.9B.
January 26, 2015
17:34 EDTACTActavis registration statement for Allergan acquisition declared effective
Subscribe for More Information
16:15 EDTPFEPfizer commits to lower price for Prevenar 13 in developing countries
Subscribe for More Information
15:40 EDTPFENotable companies reporting before tomorrow's open
Subscribe for More Information
13:29 EDTPFEEarnings Preview: Pfizer set to report Q4 results as generics impact Celebrex
Subscribe for More Information
11:00 EDTMYLMylan expands Hepatitis C licensing agreement with Gilead
Mylan (MYL) announced that its subsidiary Mylan Laboratories Limited is expanding its hepatitis C licensing agreement with Gilead Sciences (GILD) to include the non-exclusive rights to manufacture and distribute the investigational NS5A inhibitor GS-5816 and single tablet regimen of sofosbuvir/GS-5816, once approved, in 91 developing countries. The single tablet regimen is being evaluated in Phase 3 clinical studies for the treatment of all six genotypes of hepatitis C. If approved by regulatory authorities, the sofosbuvir/GS-5816 regimen would become the first all-oral single tablet regimen for all hepatitis C genotypes. A pan-genotypic therapeutic option is particularly important for developing countries, where genotype testing is often unreliable or not readily available. This agreement is in addition to the licensing and technology transfer agreement that Mylan entered into with Gilead in September 2014, which grants Mylan the non-exclusive rights to manufacture and distribute sofosbuvir and ledipasvir/sofosbuvir in 91 developing countries. Mylan also partners with Gilead on expanding access to high quality, affordable antiretrovirals for the treatment of HIV/AIDS in India and other developing countries.
07:34 EDTACTActavis to acquire Auden Mckenzie for GBP306M accretive in FY15
Subscribe for More Information
January 23, 2015
16:08 EDTPFETeva volatility elevated, Pfizer approached late last year, Bloomberg says
Teva (TEVA) overall option implied volatility of 25 compares to its 26-week average of 23 according to Track Data, suggesting large price movement into Pfizer (PFE) approach late last year, Bloomberg says.
16:04 EDTPFETeva rebuffed Pfizer approach late last year, Bloomberg says
Subscribe for More Information
January 22, 2015
11:23 EDTPFEPfizer says CHMP adopted positive opinion on Prevenar 13 expansion
Subscribe for More Information
05:57 EDTVRX, ACTActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
January 21, 2015
12:30 EDTACT, VRX, PFEGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:22 EDTACTActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information
January 20, 2015
14:37 EDTMYLTeva generic competition to Copaxone pushed out by ruling, says BMO Capital
Subscribe for More Information
12:56 EDTMYLMylan says continues to believe '808 patent is 'invalid'
Subscribe for More Information
10:40 EDTMYLMomenta Pharma sinks after Supreme Court rules on Copaxone
Subscribe for More Information
05:34 EDTACTActavis reports positive Phase III results for cariprazine
Gedeon Richter and Actavis announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia. There were 101 patients randomized to cariprazine 3 to 9 mg per day and 99 randomized to placebo. The primary efficacy measure was time to first relapse during the double-blind period. There were 25 relapses in the cariprazine group versus 47 relapses in the placebo group. Treatment with cariprazine was associated with a 55% reduction in risk of relapse versus placebo.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use